NCP 2.0 Repeat Study

Brain Health Clinical Trial

Official title:

Assessing Repeatability of the NeuroCatch Platform 2.0 Stimulus Sequences

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04661592
• Other study ID #: NCI_NCClin_004
• Status: Completed
• Phase: N/A
• Start date: November 30, 2020
• Est. completion date: August 31, 2021

Study information

• Verified date: March 2022
• Source: NeuroCatch Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The NeuroCatch Platform™ version 2.0 (NCP2.0), an investigational medical device system developed by NeuroCatch Inc., consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP; brain response to a stimulus) information.

The purpose of the study is to understand how reliable and repeatable the ERP metrics elicited by the NCP platform are within participants over multiple sessions.

Description:

A new method for creating stimulus sequences was developed for NeuroCatch™ Platform 2.0. Rather than using a set of fixed, predetermined sequences to elicit ERPs this new method draws on a database of candidate word stimuli to generate a different, random stimulus sequence each time a scan is carried out. The goal of this is to reduce habituation to the stimulus sequences which is hypothesized to improve the repeatability of the component measurements. Characterizing how individuals respond to the stimulus sequences is an important step in the validation of the generation method itself. Understanding the degree of variability and prototypical values of each ERP component is crucial to the understanding of typical brain functioning. For this type of technology to be clinically viable in quantifying brain health, the investigators must first quantify the degree to which a healthy brain naturally fluctuates in it processing capability. This study is being carried out to assess how repeatable the ERPs elicited by the new method are while also considering the impact of intraindividual variability observed in previous investigations. Thus, by comparing the results of the scans over time, an assessment of the reliability of the new stimulus sequences can be made.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: August 31, 2021
• Est. primary completion date: March 31, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

1. Any sex, at least 19 years of age or older

2. Able to understand the informed consent form, study procedures and willing to participate in study

3. Able to remain seated and focused for 7 minutes

4. In good health with no history of clinically relevant neurological illness or injury in the last 5 years

Exclusion Criteria:

1. Requires the use of hearing aids or a cochlear implant, diagnosed with tinnitus that is currently active, or has temporary damage to earing (e.g. punctured ear drum). Or unable to detect a 740Hz tone played at 85dB in both ears.

2. Implanted pacemaker or implanted electrical stimulators

3. Metal or plastic implants in the skull, excluding dental/facial implants

4. Exposed to an investigational drug or device 30 days prior to start in this study, or concurrent or planned use of investigational drug or device while enrolled in this study

5. Not proficient in English language

6. Diagnosed epilepsy or history of seizures

7. If female and of child-bearing potential: pregnant, suspected or planning to become pregnant or breast-feeding

8. Unhealthy scalp (apparent open wounds and/or bruised or weakened skin)

Related Conditions & MeSH terms

• Brain Health

Intervention

Device:
• NeuroCatch Platform
To elicit the ERP components of interest in this study (N100, P300, N400), proprietary auditory stimulus sequences will be administered using the NeuroCatch™ Platform version 2.0, an investigational medical device. Each sequence consists of tones and word pairs to elicit the various components of interest. Version 2.0 of the NeuroCatch™ Platform consists of a computerized acquisition software which presents the stimulus, acquires the data and presents the amplitude and latency values of the ERP components (N100, N400, P300)

Locations

Country	Name	City	State
Canada	HealthTech Connex Inc. Centre for Neurology Studies	Surrey	British Columbia

Sponsors (1)

Lead Sponsor	Collaborator
NeuroCatch Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in amplitudes of the N100 ERP acquired using the NeuroCatch™ Platform over 2 weeks - repeatability	Amplitude (response size) will be measured in microvolts. The statistic being used to measure the repeatability over three time points will be the intraclass correlation coefficient (ICC). Specifically, the two-way mixed single measures absolute agreement type of ICC (denoted as ICC(A,1)) will be used in this analysis.	Baseline, +1 Week, +2 Weeks
Primary	Change in amplitudes of the N100 ERP acquired using the NeuroCatch™ Platform over 2 weeks - variability	Amplitude (response size) will be measured in microvolts. The statistic being used to measure the variability over three time points will be the group-mean of the individual standard deviations of the measures over the three time points	Baseline, +1 Week, +2 Weeks
Primary	Change in Latency of the N100 ERP acquired using the NeuroCatch™ Platform over 2 weeks - repeatability	Latency (response speed) will be measured in milliseconds. The statistic being used to measure the repeatability over three time points will be the intraclass correlation coefficient (ICC). Specifically, the two-way mixed single measures absolute agreement type of ICC (denoted as ICC(A,1)) will be used in this analysis.	Baseline, +1 Week, +2 Weeks
Primary	Change in Latency of the N100 ERP acquired using the NeuroCatch™ Platform over 2 weeks - variability	Latency (response speed) will be measured in milliseconds. The statistic being used to measure the variability over three time points will be the group-mean of the individual standard deviations of the measures over the three time points	Baseline, +1 Week, +2 Weeks
Primary	Change in amplitudes of the P300 ERP acquired using the NeuroCatch™ Platform over 2 weeks - repeatability	Amplitude (response size) will be measured in microvolts. The statistic being used to measure the repeatability over three time points will be the intraclass correlation coefficient (ICC). Specifically, the two-way mixed single measures absolute agreement type of ICC (denoted as ICC(A,1)) will be used in this analysis.	Baseline, +1 Week, +2 Weeks
Primary	Change in amplitudes of the P300 ERP acquired using the NeuroCatch™ Platform over 2 weeks - variability	Amplitude (response size) will be measured in microvolts. The statistic being used to measure the variability over three time points will be the group-mean of the individual standard deviations of the measures over the three time points	Baseline, +1 Week, +2 Weeks
Primary	Change in Latency of the P300 ERP acquired using the NeuroCatch™ Platform over 2 weeks - repeatability	Latency (response speed) will be measured in milliseconds. The statistic being used to measure the repeatability over three time points will be the intraclass correlation coefficient (ICC). Specifically, the two-way mixed single measures absolute agreement type of ICC (denoted as ICC(A,1)) will be used in this analysis.	Baseline, +1 Week, +2 Weeks
Primary	Change in Latency of the P300 ERP acquired using the NeuroCatch™ Platform over 2 weeks - variability	Latency (response speed) will be measured in milliseconds. The statistic being used to measure the variability over three time points will be the group-mean of the individual standard deviations of the measures over the three time points	Baseline, +1 Week, +2 Weeks
Primary	Change in amplitudes of the N400 ERP acquired using the NeuroCatch™ Platform over 2 weeks - repeatability	Amplitude (response size) will be measured in microvolts. The statistic being used to measure the repeatability over three time points will be the intraclass correlation coefficient (ICC). Specifically, the two-way mixed single measures absolute agreement type of ICC (denoted as ICC(A,1)) will be used in this analysis.	Baseline, +1 Week, +2 Weeks
Primary	Change in amplitudes of the N400 ERP acquired using the NeuroCatch™ Platform over 2 weeks - variability	Amplitude (response size) will be measured in microvolts. The statistic being used to measure the variability over three time points will be the group-mean of the individual standard deviations of the measures over the three time points	Baseline, +1 Week, +2 Weeks
Primary	Change in Latency of the N400 ERP acquired using the NeuroCatch™ Platform over 2 weeks - repeatability	Latency (response speed) will be measured in milliseconds. The statistic being used to measure the repeatability over three time points will be the intraclass correlation coefficient (ICC). Specifically, the two-way mixed single measures absolute agreement type of ICC (denoted as ICC(A,1)) will be used in this analysis.	Baseline, +1 Week, +2 Weeks
Primary	Change in Latency of the N400 ERP acquired using the NeuroCatch™ Platform over 2 weeks - variability	Latency (response speed) will be measured in milliseconds. The statistic being used to measure the variability over three time points will be the group-mean of the individual standard deviations of the measures over the three time points	Baseline, +1 Week, +2 Weeks
Secondary	Collection and evaluation of adverse events and adverse device effects	Evaluation of safety and tolerability of the NeuroCatch™ Platform device	At time of event
Secondary	Change in hours of sleep of the day of scan	Secondary statistical analyses will explore the correlation between hours of sleep on the day of scan with changes in ERP measures (primary outcomes) across the sample	Baseline, +1 Week, +2 Weeks
Secondary	Change in perceived mood on the day of scan	Secondary statistical analyses will explore the correlation between perceived mood (ranked on a scale of 0-100) on the day of scan with changes in ERP measures (primary outcomes) across the sample	Baseline, +1 Week, +2 Weeks